25 publications
Name | Date | Type | Actions |
---|---|---|---|
Third quarter revenues: €132 million |
14/10/2021 | Public releases | |
2021 first half results 2021 Half year results |
29/07/2021 | Public releases | |
Availability of the 2020 universal registration document Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021. |
28/04/2021 | Public releases | |
Q1 2021 sales Q1 2021 sales : €128M (up 28% at constant exchange rates, up 24% as reported)
Q1 2021 essential sales : €72.6M (up 38% at constant exchange rates, up 36% as reported)
|
15/04/2021 | Public releases | |
2020 annual results 2020 sales: €427.5m (up 8.0% as reported)
EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m
|
01/04/2021 | Public releases | |
Vetoquinol wins the Animal Pharm’s award for best European company 2020 February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm. |
08/02/2021 | Public releases | |
Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health. |
08/02/2021 | press release excluding results | |
2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate) Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.” |
21/01/2021 | Public releases | |
Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements. |
18/01/2021 | Public releases | |
Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health. |
11/01/2021 | Public releases | |
Vétoquinol announces opening of its first decentralized R&D center in Canada |
17/12/2007 | Public releases | |
Vétoquinol to market and distribute Vetprofen in the United States |
28/11/2007 | Public releases | |
3rd quarter revenues confirm promise of For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the |
25/10/2007 | Public releases | |
Reports very good first half, confirming that 2007 performance is set to surpass targets |
27/09/2007 | Public releases | |
Presentation of Vétoquinol’s results for the first half of 2007 2007 Half year results |
27/09/2007 | Public releases | |
Rapport semestriel 2007 « narratif » (french) Suite à la publication du 26 juillet dernier, Vétoquinol a réalisé au 1er semestre 2007 un |
31/08/2007 | Public releases | |
Business is strong in first-half of 2007 : + 12.9% 2007 Half year Financial Report |
26/07/2007 | Public releases | |
Vétoquinol creates a subsidiary in Portugal |
05/07/2007 | Public releases | |
2006 Financial Report Le chiffre d’affaires s’est accru de 7,6% par rapport à l’exercice précédent. |
04/06/2007 | Public releases | |
Activity Report 2006 |
04/06/2007 | Public releases | |
Annual earnings for 2006: a year of good performance |
23/04/2007 | Public releases | |
Présentation des résultats 2006 de Vétoquinol (french) |
23/04/2007 | Public releases | |
Vétoquinol reports one of its industry’ strongest growth performances in 2006 |
03/04/2007 | Public releases | |
Sustained revenue growth in 2006 |
15/02/2007 | Public releases | |
Vétoquinol strengthens its position in the United States |
02/01/2007 | Public releases |